Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto™.
Tony GeorgievLucrezia PrincipiAndrea GalbiatiEttore GilardoniDario NeriSamuele CazzamalliPublished in: European journal of nuclear medicine and molecular imaging (2024)
The therapeutic efficacy of Pluvicto™ at low radioactive doses can be effectively enhanced by the combination with L19-IL2. Our findings warrant further clinical exploration of this novel combination modality.
Keyphrases